Do analysts prefer ABVC or RFL?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ABVC BioPharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Rafael 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ABVC or RFL more profitable?

ABVC BioPharma has a net margin of 0.00% compared to Rafael's net margin of -3,321.74%. Rafael's return on equity of -41.27% beat ABVC BioPharma's return on equity. Company Net Margins Return on Equity Return on Assets ABVC BioPharma N/A -47.68% -30.97% Rafael -3,321.74% -41.27% -35.32%

Does the media favor ABVC or RFL?

In the previous week, Rafael had 1 more articles in the media than ABVC BioPharma. MarketBeat recorded 3 mentions for Rafael and 2 mentions for ABVC BioPharma. ABVC BioPharma's average media sentiment score of 0.00 beat Rafael's score of -0.37 indicating that ABVC BioPharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ABVC BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Rafael 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Do analysts recommend PLYX or ABVC?

Polaryx Therapeutics currently has a consensus price target of $7.67, indicating a potential upside of 283.33%. Given Polaryx Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Polaryx Therapeutics is more favorable than ABVC BioPharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Polaryx Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.60 ABVC BioPharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is PLYX or ABVC more profitable?

Polaryx Therapeutics' return on equity of 0.00% beat ABVC BioPharma's return on equity. Company Net Margins Return on Equity Return on Assets Polaryx Therapeutics N/A N/A N/A ABVC BioPharma N/A -47.68% -30.97%

Is MIST or ABVC more profitable?

ABVC BioPharma's return on equity of -47.68% beat Milestone Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Milestone Pharmaceuticals N/A -288.33% -58.27% ABVC BioPharma N/A -47.68% -30.97%

Does the media prefer MIST or ABVC?

In the previous week, Milestone Pharmaceuticals had 2 more articles in the media than ABVC BioPharma. MarketBeat recorded 4 mentions for Milestone Pharmaceuticals and 2 mentions for ABVC BioPharma. Milestone Pharmaceuticals' average media sentiment score of 0.00 equaled ABVC BioPharma'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Milestone Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ABVC BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer PYPD or ABVC?

PolyPid currently has a consensus price target of $11.33, suggesting a potential upside of 123.54%. Given PolyPid's stronger consensus rating and higher possible upside, research analysts plainly believe PolyPid is more favorable than ABVC BioPharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PolyPid 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 ABVC BioPharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is PYPD or ABVC more profitable?

ABVC BioPharma's return on equity of -47.68% beat PolyPid's return on equity. Company Net Margins Return on Equity Return on Assets PolyPid N/A -311.08% -150.83% ABVC BioPharma N/A -47.68% -30.97%

Does the media refer more to PYPD or ABVC?

In the previous week, PolyPid had 1 more articles in the media than ABVC BioPharma. MarketBeat recorded 3 mentions for PolyPid and 2 mentions for ABVC BioPharma. PolyPid's average media sentiment score of 0.49 beat ABVC BioPharma's score of 0.00 indicating that PolyPid is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PolyPid 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ABVC BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer ABVC or NTRB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ABVC BioPharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Nutriband 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is ABVC or NTRB more profitable?

ABVC BioPharma has a net margin of 0.00% compared to Nutriband's net margin of -430.35%. ABVC BioPharma's return on equity of -47.68% beat Nutriband's return on equity. Company Net Margins Return on Equity Return on Assets ABVC BioPharma N/A -47.68% -30.97% Nutriband -430.35% -109.07% -95.54%

Does the media favor ABVC or NTRB?

In the previous week, Nutriband had 1 more articles in the media than ABVC BioPharma. MarketBeat recorded 3 mentions for Nutriband and 2 mentions for ABVC BioPharma. ABVC BioPharma's average media sentiment score of 0.00 equaled Nutriband'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ABVC BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nutriband 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

ABVC BioPharma (ABVC) Competitors

$1.00 +0.02 (+2.04%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$1.01 +0.01 (+0.70%)

As of 10/9/2026 07:30 PM Eastern

Compare

ABVC vs. RFL, PLYX, MIST, PYPD, and NTRB

Should you buy ABVC BioPharma stock or one of its competitors? ABVC BioPharma's main competitors and comparable companies include Rafael (RFL), Polaryx Therapeutics (PLYX), Milestone Pharmaceuticals (MIST), PolyPid (PYPD), and Nutriband (NTRB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does ABVC BioPharma compare to Rafael?

ABVC BioPharma (NASDAQ:ABVC) and Rafael (NYSE:RFL) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, profitability, dividends, media sentiment and institutional ownership.

In the previous week, Rafael had 1 more articles in the media than ABVC BioPharma. MarketBeat recorded 3 mentions for Rafael and 2 mentions for ABVC BioPharma. ABVC BioPharma's average media sentiment score of 0.00 beat Rafael's score of -0.37 indicating that ABVC BioPharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ABVC BioPharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Rafael	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

ABVC BioPharma has a beta of 0.51, indicating that its share price is 49% less volatile than the broader market. Comparatively, Rafael has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market.

11.4% of ABVC BioPharma shares are owned by institutional investors. Comparatively, 11.3% of Rafael shares are owned by institutional investors. 19.0% of ABVC BioPharma shares are owned by company insiders. Comparatively, 32.9% of Rafael shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ABVC BioPharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Rafael	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

ABVC BioPharma has higher earnings, but lower revenue than Rafael. ABVC BioPharma is trading at a lower price-to-earnings ratio than Rafael, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ABVC BioPharma	$510K	52.33	-$7.91M	-$0.30	N/A
Rafael	$920K	91.17	-$30.52M	-$0.68	N/A

ABVC BioPharma has a net margin of 0.00% compared to Rafael's net margin of -3,321.74%. Rafael's return on equity of -41.27% beat ABVC BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ABVC BioPharma	N/A	-47.68%	-30.97%
Rafael	-3,321.74%	-41.27%	-35.32%

Summary

ABVC BioPharma beats Rafael on 7 of the 13 factors compared between the two stocks.

How does ABVC BioPharma compare to Polaryx Therapeutics?

Polaryx Therapeutics (NASDAQ:PLYX) and ABVC BioPharma (NASDAQ:ABVC) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, media sentiment, institutional ownership, earnings, dividends and profitability.

11.4% of ABVC BioPharma shares are held by institutional investors. 45.8% of Polaryx Therapeutics shares are held by company insiders. Comparatively, 19.0% of ABVC BioPharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Polaryx Therapeutics currently has a consensus price target of $7.67, indicating a potential upside of 283.33%. Given Polaryx Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Polaryx Therapeutics is more favorable than ABVC BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Polaryx Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
ABVC BioPharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, ABVC BioPharma had 1 more articles in the media than Polaryx Therapeutics. MarketBeat recorded 2 mentions for ABVC BioPharma and 1 mentions for Polaryx Therapeutics. Polaryx Therapeutics' average media sentiment score of 1.34 beat ABVC BioPharma's score of 0.00 indicating that Polaryx Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Polaryx Therapeutics	Positive
ABVC BioPharma	Neutral

Polaryx Therapeutics' return on equity of 0.00% beat ABVC BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Polaryx Therapeutics	N/A	N/A	N/A
ABVC BioPharma	N/A	-47.68%	-30.97%

ABVC BioPharma has higher revenue and earnings than Polaryx Therapeutics. Polaryx Therapeutics is trading at a lower price-to-earnings ratio than ABVC BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Polaryx Therapeutics	N/A	N/A	-$8.98M	-$0.08	N/A
ABVC BioPharma	$510K	52.33	-$7.91M	-$0.30	N/A

Summary

Polaryx Therapeutics beats ABVC BioPharma on 9 of the 14 factors compared between the two stocks.

How does ABVC BioPharma compare to Milestone Pharmaceuticals?

Milestone Pharmaceuticals (NASDAQ:MIST) and ABVC BioPharma (NASDAQ:ABVC) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations, profitability and media sentiment.

Milestone Pharmaceuticals has a beta of 1.01, suggesting that its share price is 1% more volatile than the broader market. Comparatively, ABVC BioPharma has a beta of 0.51, suggesting that its share price is 49% less volatile than the broader market.

ABVC BioPharma has lower revenue, but higher earnings than Milestone Pharmaceuticals. ABVC BioPharma is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Milestone Pharmaceuticals	$1.55M	61.45	-$63.06M	-$0.69	N/A
ABVC BioPharma	$510K	52.33	-$7.91M	-$0.30	N/A

86.2% of Milestone Pharmaceuticals shares are owned by institutional investors. Comparatively, 11.4% of ABVC BioPharma shares are owned by institutional investors. 5.0% of Milestone Pharmaceuticals shares are owned by insiders. Comparatively, 19.0% of ABVC BioPharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Milestone Pharmaceuticals had 2 more articles in the media than ABVC BioPharma. MarketBeat recorded 4 mentions for Milestone Pharmaceuticals and 2 mentions for ABVC BioPharma. Milestone Pharmaceuticals' average media sentiment score of 0.00 equaled ABVC BioPharma'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Milestone Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ABVC BioPharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ABVC BioPharma's return on equity of -47.68% beat Milestone Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Milestone Pharmaceuticals	N/A	-288.33%	-58.27%
ABVC BioPharma	N/A	-47.68%	-30.97%

Milestone Pharmaceuticals presently has a consensus target price of $6.40, suggesting a potential upside of 736.60%. Given Milestone Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Milestone Pharmaceuticals is more favorable than ABVC BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Milestone Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
ABVC BioPharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Milestone Pharmaceuticals beats ABVC BioPharma on 10 of the 15 factors compared between the two stocks.

How does ABVC BioPharma compare to PolyPid?

PolyPid (NASDAQ:PYPD) and ABVC BioPharma (NASDAQ:ABVC) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and media sentiment.

PolyPid has a beta of 1.38, meaning that its stock price is 38% more volatile than the broader market. Comparatively, ABVC BioPharma has a beta of 0.51, meaning that its stock price is 49% less volatile than the broader market.

ABVC BioPharma has higher revenue and earnings than PolyPid. PolyPid is trading at a lower price-to-earnings ratio than ABVC BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PolyPid	N/A	N/A	-$34.17M	-$1.48	N/A
ABVC BioPharma	$510K	52.33	-$7.91M	-$0.30	N/A

PolyPid currently has a consensus price target of $11.33, suggesting a potential upside of 123.54%. Given PolyPid's stronger consensus rating and higher possible upside, research analysts plainly believe PolyPid is more favorable than ABVC BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PolyPid	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
ABVC BioPharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, PolyPid had 1 more articles in the media than ABVC BioPharma. MarketBeat recorded 3 mentions for PolyPid and 2 mentions for ABVC BioPharma. PolyPid's average media sentiment score of 0.49 beat ABVC BioPharma's score of 0.00 indicating that PolyPid is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PolyPid	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ABVC BioPharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

26.5% of PolyPid shares are held by institutional investors. Comparatively, 11.4% of ABVC BioPharma shares are held by institutional investors. 24.7% of PolyPid shares are held by company insiders. Comparatively, 19.0% of ABVC BioPharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

ABVC BioPharma's return on equity of -47.68% beat PolyPid's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PolyPid	N/A	-311.08%	-150.83%
ABVC BioPharma	N/A	-47.68%	-30.97%

Summary

PolyPid beats ABVC BioPharma on 8 of the 14 factors compared between the two stocks.

How does ABVC BioPharma compare to Nutriband?

ABVC BioPharma (NASDAQ:ABVC) and Nutriband (NASDAQ:NTRB) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, media sentiment, institutional ownership, dividends, profitability and earnings.

11.4% of ABVC BioPharma shares are owned by institutional investors. Comparatively, 19.7% of Nutriband shares are owned by institutional investors. 19.0% of ABVC BioPharma shares are owned by company insiders. Comparatively, 52.2% of Nutriband shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ABVC BioPharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Nutriband	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

ABVC BioPharma has a beta of 0.51, suggesting that its stock price is 49% less volatile than the broader market. Comparatively, Nutriband has a beta of 1.92, suggesting that its stock price is 92% more volatile than the broader market.

ABVC BioPharma has higher earnings, but lower revenue than Nutriband. Nutriband is trading at a lower price-to-earnings ratio than ABVC BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ABVC BioPharma	$510K	52.33	-$7.91M	-$0.30	N/A
Nutriband	$2.04M	39.64	-$8.23M	-$0.53	N/A

In the previous week, Nutriband had 1 more articles in the media than ABVC BioPharma. MarketBeat recorded 3 mentions for Nutriband and 2 mentions for ABVC BioPharma. ABVC BioPharma's average media sentiment score of 0.00 equaled Nutriband'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ABVC BioPharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nutriband	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ABVC BioPharma has a net margin of 0.00% compared to Nutriband's net margin of -430.35%. ABVC BioPharma's return on equity of -47.68% beat Nutriband's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ABVC BioPharma	N/A	-47.68%	-30.97%
Nutriband	-430.35%	-109.07%	-95.54%

Summary

ABVC BioPharma beats Nutriband on 7 of the 13 factors compared between the two stocks.

Get ABVC BioPharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABVC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ABVC vs. The Competition

Export

Metric	ABVC BioPharma	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$26.16M	$12.31B	$7.16B	$13.21B
Dividend Yield	N/A	2.64%	2.53%	16.37%
P/E Ratio	-3.33	797.58	275.02	26.16
Price / Sales	52.33	939.75	635.97	107.44
Price / Cash	N/A	85.97	76.38	53.09
Price / Book	1.92	10.71	11.22	6.33
Net Income	-$7.91M	$2.84B	$3.50B	$382.15M
7 Day Performance	-0.99%	-0.94%	-0.89%	-1.40%
1 Month Performance	2.44%	-4.89%	-4.42%	-3.47%
1 Year Performance	-67.11%	-4.12%	7.03%	1.18%

ABVC BioPharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ABVC ABVC BioPharma	0.9237 of 5 stars	$1.00 +2.0%	N/A	-69.6%	$26.16M	$510K	N/A	19
RFL Rafael	0.7223 of 5 stars	$1.33 -34.7%	N/A	+19.5%	$105.56M	$920K	N/A	23	High Trading Volume
PLYX Polaryx Therapeutics	2.6907 of 5 stars	$2.07 flat	$7.67 +270.4%	N/A	$103.18M	N/A	N/A	11	Positive News
MIST Milestone Pharmaceuticals	2.3492 of 5 stars	$0.87 +5.6%	$6.40 +639.3%	-63.4%	$102.09M	$1.55M	N/A	38	News Coverage
PYPD PolyPid	2.4569 of 5 stars	$5.27 -0.4%	$11.33 +115.1%	+52.3%	$100.95M	N/A	N/A	75	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ABVC) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ABVC BioPharma (ABVC) Competitors

ABVC vs. RFL, PLYX, MIST, PYPD, and NTRB

How does ABVC BioPharma compare to Rafael?

Summary

How does ABVC BioPharma compare to Polaryx Therapeutics?

Summary

How does ABVC BioPharma compare to Milestone Pharmaceuticals?

Summary

How does ABVC BioPharma compare to PolyPid?

Summary

How does ABVC BioPharma compare to Nutriband?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABVC vs. The Competition

ABVC BioPharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ABVC BioPharma (ABVC) Competitors

ABVC vs. RFL, PLYX, MIST, PYPD, and NTRB

How does ABVC BioPharma compare to Rafael?

Does the media favor ABVC or RFL?

Which has more risk & volatility, ABVC or RFL?

Do institutionals and insiders believe in ABVC or RFL?

Do analysts prefer ABVC or RFL?

Which has higher valuation and earnings, ABVC or RFL?

Is ABVC or RFL more profitable?

Summary

How does ABVC BioPharma compare to Polaryx Therapeutics?

Do insiders and institutionals believe in PLYX or ABVC?

Do analysts recommend PLYX or ABVC?

Does the media favor PLYX or ABVC?

Is PLYX or ABVC more profitable?

Which has higher valuation & earnings, PLYX or ABVC?

Summary

How does ABVC BioPharma compare to Milestone Pharmaceuticals?

Which has more risk and volatility, MIST or ABVC?

Which has higher valuation & earnings, MIST or ABVC?

Do institutionals and insiders hold more shares of MIST or ABVC?

Does the media prefer MIST or ABVC?

Is MIST or ABVC more profitable?

Do analysts rate MIST or ABVC?

Summary

How does ABVC BioPharma compare to PolyPid?

Which has more risk and volatility, PYPD or ABVC?

Which has higher earnings & valuation, PYPD or ABVC?

Do analysts prefer PYPD or ABVC?

Does the media refer more to PYPD or ABVC?

Do institutionals & insiders have more ownership in PYPD or ABVC?

Is PYPD or ABVC more profitable?

Summary

How does ABVC BioPharma compare to Nutriband?

Do insiders and institutionals have more ownership in ABVC or NTRB?

Do analysts prefer ABVC or NTRB?

Which has more volatility & risk, ABVC or NTRB?

Which has preferable earnings and valuation, ABVC or NTRB?

Does the media favor ABVC or NTRB?

Is ABVC or NTRB more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABVC vs. The Competition

ABVC BioPharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools